{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:03:26Z","timestamp":1791072206719,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR001442"],"award-info":[{"award-number":["UL1TR001442"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH\/NIBIB K08 EB026503, NIH\/NCI U54CA132384, U54CA132379"],"award-info":[{"award-number":["NIH\/NIBIB K08 EB026503, NIH\/NCI U54CA132384, U54CA132379"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001960","name":"American Society for Radiation Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001960","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019775","name":"Moores Cancer Center, UC San Diego Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019775","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006098","name":"Radiological Society of North America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011981","name":"American College of Radiation Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011981","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In a recent phase III randomized control trial, delivering a focal radiotherapy (RT) boost to tumors visible on MRI was shown to improve disease-free survival and regional\/distant metastasis-free survival for patients with prostate cancer\u2014without increasing toxicity. The aim of this study was to assess how widely this technique is being applied in current practice, as well as physicians\u2019 perceived barriers toward its implementation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We invited radiation oncologists to complete an online questionnaire assessing their use of intraprostatic focal boost in December 2022 and February 2023. To include perspectives from a broad range of practice settings, the invitation was distributed to radiation oncologists worldwide via email list, group text platform, and social media.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>263 radiation oncologist participants responded. The highest-represented countries were the United States (42%), Mexico (13%), and the United Kingdom (8%). The majority of participants worked at an academic medical center (52%) and considered their practice to be at least partially genitourinary (GU)-subspecialized (74%). Overall, 43% of participants reported routinely using intraprostatic focal boost. Complete GU-subspecialists were more likely to implement focal boost, with 61% reporting routine use. In both high-income and low-to-middle-income countries, less than half of participants routinely use focal boost. The most cited barriers were concerns about registration accuracy between MRI and CT (37%), concerns about risk of additional toxicity (35%), and challenges to accessing high-quality MRI (29%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Two years following publication of a randomized trial of patient benefit without increased toxicity, almost half of the radiation oncologists surveyed are now routinely offering focal RT boost. Further adoption of this technique might be aided by increased access to high-quality MRI, better registration algorithms of MRI to CT simulation images, physician education on benefit-to-harm ratio, and training on contouring prostate lesions on MRI.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-023-02375-5","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T04:23:53Z","timestamp":1699676633000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Use of focal radiotherapy boost for prostate cancer: radiation oncologists\u2019 perspectives and perceived barriers to implementation"],"prefix":"10.1186","volume":"18","author":[{"given":"Allison Y.","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asona J.","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia C.","family":"Kamran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar U.","family":"Kishan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedang","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu","family":"Nagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Seible","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Stish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison C.","family":"Tree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler M.","family":"Seibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,11]]},"reference":[{"issue":"7","key":"2375_CR1","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1200\/JCO.20.02873","volume":"39","author":"LGW Kerkmeijer","year":"2021","unstructured":"Kerkmeijer LGW, Groen VH, Pos FJ, et al. Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial. JCO. 2021;39(7):787\u201396. https:\/\/doi.org\/10.1200\/JCO.20.02873.","journal-title":"JCO"},{"issue":"3","key":"2375_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.eururo.2021.12.012","volume":"82","author":"VH Groen","year":"2022","unstructured":"Groen VH, Haustermans K, Pos FJ, et al. Patterns of failure following external beam radiotherapy with or without an additional focal boost in the randomized controlled FLAME trial for localized prostate cancer. Eur Urol. 2022;82(3):252\u20137. https:\/\/doi.org\/10.1016\/j.eururo.2021.12.012.","journal-title":"Eur Urol"},{"key":"2375_CR3","unstructured":"World Bank Open Data | Data. https:\/\/data.worldbank.org\/. Accessed 30 Jan 2023."},{"issue":"11","key":"2375_CR4","doi-asserted-by":"publisher","first-page":"e2129647","DOI":"10.1001\/jamanetworkopen.2021.29647","volume":"4","author":"DI Pryor","year":"2021","unstructured":"Pryor DI, Martin JM, Millar JL, et al. Evaluation of hypofractionated radiation therapy use and patient-reported outcomes in men with nonmetastatic prostate cancer in Australia and New Zealand. JAMA Netw Open. 2021;4(11):e2129647. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.29647.","journal-title":"JAMA Netw Open"},{"key":"2375_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.4267","author":"JB Yu","year":"2023","unstructured":"Yu JB, Sun Y, Jia AY, et al. Increasing use of shorter-course radiotherapy for prostate cancer. JAMA Oncol. 2023. https:\/\/doi.org\/10.1001\/jamaoncol.2023.4267.","journal-title":"JAMA Oncol"},{"issue":"10","key":"2375_CR6","doi-asserted-by":"publisher","first-page":"e2337165","DOI":"10.1001\/jamanetworkopen.2023.37165","volume":"6","author":"SA Qureshy","year":"2023","unstructured":"Qureshy SA, Diven MA, Ma X, et al. Differential use of radiotherapy fractionation regimens in prostate cancer. JAMA Netw Open. 2023;6(10):e2337165. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.37165.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2375_CR7","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.ijrobp.2014.09.032","volume":"90","author":"R Jagsi","year":"2014","unstructured":"Jagsi R, Falchook AD, Hendrix LH, Curry H, Chen RC. Adoption of hypofractionated radiation therapy for breast cancer after publication of randomized trials. Int J Radiat Oncol Biol Phys. 2014;90(5):1001\u20139. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.09.032.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"2375_CR8","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1007\/s00066-020-01730-9","volume":"197","author":"D Krug","year":"2021","unstructured":"Krug D, Vonthein R, Schreiber A, et al. Impact of guideline changes on adoption of hypofractionation and breast cancer patient characteristics in the randomized controlled HYPOSIB trial. Strahlenther Onkol. 2021;197(9):802\u201311. https:\/\/doi.org\/10.1007\/s00066-020-01730-9.","journal-title":"Strahlenther Onkol"},{"issue":"5","key":"2375_CR9","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.clon.2020.12.008","volume":"33","author":"GN Marta","year":"2021","unstructured":"Marta GN, Ramiah D, Kaidar-Person O, et al. The financial impact on reimbursement of moderately hypofractionated postoperative radiation therapy for breast cancer: an international consortium report. Clin Oncol. 2021;33(5):322\u201330. https:\/\/doi.org\/10.1016\/j.clon.2020.12.008.","journal-title":"Clin Oncol"},{"issue":"5","key":"2375_CR10","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.clon.2022.03.002","volume":"34","author":"K Aitken","year":"2022","unstructured":"Aitken K, Mukherjee S. When less is more: the rising tide of hypofractionation. Clin Oncol. 2022;34(5):277\u20139. https:\/\/doi.org\/10.1016\/j.clon.2022.03.002.","journal-title":"Clin Oncol"},{"issue":"4","key":"2375_CR11","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1109\/JBHI.2016.2581881","volume":"21","author":"F Commandeur","year":"2017","unstructured":"Commandeur F, Simon A, Mathieu R, et al. MRI to CT prostate registration for improved targeting in cancer external beam radiotherapy. IEEE J Biomed Health Inform. 2017;21(4):1015\u201326. https:\/\/doi.org\/10.1109\/JBHI.2016.2581881.","journal-title":"IEEE J Biomed Health Inform"},{"issue":"3","key":"2375_CR12","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.ijrobp.2005.02.022","volume":"63","author":"JM Schallenkamp","year":"2005","unstructured":"Schallenkamp JM, Herman MG, Kruse JJ, Pisansky TM. Prostate position relative to pelvic bony anatomy based on intraprostatic gold markers and electronic portal imaging. Int J Radiat Oncol Biol Phys. 2005;63(3):800\u201311. https:\/\/doi.org\/10.1016\/j.ijrobp.2005.02.022.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"61","key":"2375_CR13","doi-asserted-by":"publisher","first-page":"061907","DOI":"10.1118\/1.4807087","volume":"40","author":"AS Korsager","year":"2013","unstructured":"Korsager AS, Carl J, \u00d8stergaard LR. MR-CT registration using a Ni-Ti prostate stent in image-guided radiotherapy of prostate cancer. Med Phys. 2013;40(61):061907. https:\/\/doi.org\/10.1118\/1.4807087.","journal-title":"Med Phys"},{"issue":"3","key":"2375_CR14","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1120\/jacmp.v17i3.6088","volume":"17","author":"AS Korsager","year":"2016","unstructured":"Korsager AS, Carl J, \u00d8stergaard LR. Comparison of manual and automatic MR-CT registration for radiotherapy of prostate cancer. J Appl Clin Med Phys. 2016;17(3):294\u2013303. https:\/\/doi.org\/10.1120\/jacmp.v17i3.6088.","journal-title":"J Appl Clin Med Phys"},{"issue":"7","key":"2375_CR15","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1088\/0031-9155\/60\/7\/2837","volume":"60","author":"H Zhong","year":"2015","unstructured":"Zhong H, Wen N, Gordon JJ, Elshaikh MA, Movsas B, Chetty IJ. An adaptive MR-CT registration method for MRI-guided prostate cancer radiotherapy. Phys Med Biol. 2015;60(7):2837\u201351. https:\/\/doi.org\/10.1088\/0031-9155\/60\/7\/2837.","journal-title":"Phys Med Biol"},{"issue":"2","key":"2375_CR16","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/jmri.27393","volume":"53","author":"CC Conlin","year":"2021","unstructured":"Conlin CC, Feng CH, Rodriguez-Soto AE, et al. Improved characterization of diffusion in normal and cancerous prostate tissue through optimization of multicompartmental signal models. J Magn Reson Imaging. 2021;53(2):628\u201339. https:\/\/doi.org\/10.1002\/jmri.27393.","journal-title":"J Magn Reson Imaging"},{"key":"2375_CR17","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.25.20162172","author":"CH Feng","year":"2020","unstructured":"Feng CH, Conlin CC, Batra K, et al. Voxel-level classification of prostate cancer using a four-compartment restriction spectrum imaging model. Oncology. 2020. https:\/\/doi.org\/10.1101\/2020.07.25.20162172.","journal-title":"Oncology"},{"key":"2375_CR18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.euros.2022.11.009","volume":"47","author":"AY Zhong","year":"2023","unstructured":"Zhong AY, Digma LA, Hussain T, et al. Automated patient-level prostate cancer detection with quantitative diffusion magnetic resonance imaging. Eur Urol Open Sci. 2023;47:20\u20138. https:\/\/doi.org\/10.1016\/j.euros.2022.11.009.","journal-title":"Eur Urol Open Sci"},{"issue":"2","key":"2375_CR19","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/jmri.25419","volume":"45","author":"RL Brunsing","year":"2017","unstructured":"Brunsing RL, Schenker-Ahmed NM, White NS, et al. Restriction spectrum imaging: an evolving imaging biomarker in prostate MRI. J Magn Reson Imaging. 2017;45(2):323\u201336. https:\/\/doi.org\/10.1002\/jmri.25419.","journal-title":"J Magn Reson Imaging"},{"key":"2375_CR20","doi-asserted-by":"publisher","DOI":"10.1101\/2022.12.13.22283420","author":"AJ Lui","year":"2022","unstructured":"Lui AJ, Kallis K, Zhong AY, et al. ReIGNITE RT boost: an international study testing the accuracy and feasibility of using restriction spectrum imaging (RSI) MRI to guide intraprostatic tumor target volume for radiotherapy boost. Oncology. 2022. https:\/\/doi.org\/10.1101\/2022.12.13.22283420.","journal-title":"Oncology"},{"issue":"2","key":"2375_CR21","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.euo.2022.10.001","volume":"6","author":"DMC Poon","year":"2023","unstructured":"Poon DMC, Yuan J, Yang B, et al. Magnetic resonance imaging\u2013guided focal boost to intraprostatic lesions using external beam radiotherapy for localized prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol. 2023;6(2):116\u201327. https:\/\/doi.org\/10.1016\/j.euo.2022.10.001.","journal-title":"Eur Urol Oncol"},{"key":"2375_CR22","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.radonc.2020.03.015","volume":"147","author":"C Draulans","year":"2020","unstructured":"Draulans C, van der Heide UA, Haustermans K, et al. Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. Radiother Oncol. 2020;147:92\u20138. https:\/\/doi.org\/10.1016\/j.radonc.2020.03.015.","journal-title":"Radiother Oncol"},{"key":"2375_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ctro.2020.08.003","volume":"25","author":"I Syndikus","year":"2020","unstructured":"Syndikus I, Cruickshank C, Staffurth J, et al. PIVOTALboost: a phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK\/16\/018). Clin Transl Radiat Oncol. 2020;25:22\u20138. https:\/\/doi.org\/10.1016\/j.ctro.2020.08.003.","journal-title":"Clin Transl Radiat Oncol"},{"key":"2375_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.radonc.2021.12.027","volume":"167","author":"VH Groen","year":"2022","unstructured":"Groen VH, van Schie M, Zuithoff NPA, et al. Urethral and bladder dose\u2013effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial. Radiother Oncol. 2022;167:127\u201332. https:\/\/doi.org\/10.1016\/j.radonc.2021.12.027.","journal-title":"Radiother Oncol"},{"issue":"1","key":"2375_CR25","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1748-5908-9-64","volume":"9","author":"B Brown","year":"2014","unstructured":"Brown B, Young J, Smith DP, et al. Clinician-led improvement in cancer care (CLICC)\u2014testing a multifaceted implementation strategy to increase evidence-based prostate cancer care: phased randomised controlled trial\u2014study protocol. Implement Sci. 2014;9(1):64. https:\/\/doi.org\/10.1186\/1748-5908-9-64.","journal-title":"Implement Sci"},{"issue":"S3","key":"2375_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/bju.14144","volume":"121","author":"AB Rutledge","year":"2018","unstructured":"Rutledge AB, McLeod N, Mehan N, et al. A clinician-centred programme for behaviour change in the optimal use of staging investigations for newly diagnosed prostate cancer. BJU Int. 2018;121(S3):22\u20137. https:\/\/doi.org\/10.1111\/bju.14144.","journal-title":"BJU Int"},{"key":"2375_CR27","doi-asserted-by":"publisher","first-page":"896885","DOI":"10.3389\/frhs.2022.896885","volume":"2","author":"AL Morena","year":"2022","unstructured":"Morena AL, Gaias LM, Larkin C. Understanding the role of clinical champions and their impact on clinician behavior change: the need for causal pathway mechanisms. FrontHealth Serv. 2022;2:896885. https:\/\/doi.org\/10.3389\/frhs.2022.896885.","journal-title":"FrontHealth Serv"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02375-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-023-02375-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02375-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T04:24:44Z","timestamp":1699676684000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-023-02375-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,11]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2375"],"URL":"https:\/\/doi.org\/10.1186\/s13014-023-02375-5","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,11]]},"assertion":[{"value":"9 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board. Participants gave consent to participate electronically.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Tree declares research funding from Elekta, Varian Medical Systems, Inc., and Accuray. Dr. Tree declares honoraria or travel assistance from Elekta, Accuray, and Janssen. Dr. Lui is a consultant for MIM software. Dr. Katz declares stock ownership with CVS Health, Dr. Reddy's Laboratories, Healthcare Services, Quest Diagnostics, Teladoc Health, Pfizer, Moderna, and Bavarian Nordic. Dr. Murthy declares research funding from Varian Medical Systems, Inc. Dr. Stish declares research funding from Varian Medical Systems, Inc. Dr. Kishan declares research funding from ViewRay, Inc., Janssen, Inc., and Point Biopharmaceuticals, as well as honoraria and\/or consulting fees from ViewRay, Inc., Janssen, Inc., Varian Medical Systems, Inc., and Boston Scientific. Dr. Seibert reports honoraria from Varian Medical Systems, Inc. and WebMD; he has an equity interest in CorTechs Labs, Inc. and serves on its Scientific Advisory Board; he has received research grants from GE Healthcare through the University of California San Diego. These companies might potentially benefit from the research results. The terms of this arrangement have been reviewed and approved by the University of California San Diego in accordance with its conflict-of-interest policies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"188"}}